Hives on back; Booster; The rash went away in about four days.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 79 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 22Dec2021 11:50 (Lot number: FE3594, Expiration Date: 28Feb2022) at the age of 79 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Prostate cancer" (unspecified if ongoing), notes: caller doesn't remember the exact date of prostate cancer diagnosis but knows occurred at age 59.; "Kidney Cancer" (unspecified if ongoing), notes: The caller states the kidney cancer was approximately 10 years ago, the caller is guessing; "Prostate Removal" (unspecified if ongoing), notes: The prostate was removed when the caller was age 59 and the caller is 79 years now.; "Kidney removal" (unspecified if ongoing), notes: kidney removal was four years ago.; "Reoccurrence of Prostate Cancer" (unspecified if ongoing), notes: underwent 6.5 weeks of radiation, this occurred about 10 years ago. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose:1, lot: EL9265, Expiration: 31May2021, Route of administration: right arm on upper part of arm, Time the Vaccination Was Given: First dose: 1030 or 1100), administration date: 27Jan2021, when the patient was 78 years old, for COVID-19 Immunization; Bnt162b2 (Dose:2, lot: EN6201, Expiration: 30Jun2021 , Route of administration: right arm, Time the Vaccination Was Given:second dose: 1030 or 1100), administration date: 17Feb2021, when the patient was 78 years old, for COVID-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 22Dec2021 11:50, outcome "unknown", described as "Booster"; URTICARIA (non-serious) with onset 23Dec2021, outcome "recovered" (27Dec2021), described as "Hives on back"; RASH (non-serious) with onset Dec2021, outcome "not recovered", described as "The rash went away in about four days.". Therapeutic measures were taken as a result of urticaria, rash.  Additional information: The caller is a consumer who was with caller's wife at a vaccination site today. The caller received Adult Pfizer Covid 19 Vaccine because the caller was a health risk at the caller's age and the number of things the caller has. The caller had kidney removed, several operations and prostate removed. The caller had enough things and had cancer three different times. The caller had a reoccurrence of prostate cancer and underwent 6.5 weeks of radiation, this occurred about 10 years ago. The caller received the booster dose Adult Pfizer Covid 19 Vaccine one week ago, on 22Dec2021. While at the vaccination site with caller's wife today, 29Dec2021, the caller mentioned to the vaccination site that the caller had a reaction after receiving the booster dose Adult Pfizer Covid 19 Vaccine. The caller had hives on back about one day after receiving the booster dose Adult Pfizer Covid 19 Vaccine. The caller clarifies the hives began on 23Dec2021, the day after the caller received the booster dose Adult Pfizer Covid 19 Vaccine. The rash went away in about four days. The caller's wife applied Benadryl to the caller's hives. The hives were on the caller's back just below the neck on the shoulder side of where the caller received the booster dose Adult Pfizer Covid 19 Vaccine. Agent asks caller if caller recovered complete from rash or with lasting effects and the caller state, there was just a small area of 10 to 12 rashes together. Adverse event did not resulted in Emergency room or physician office visit. Route of administration: right shoulder blade on right side, not blade itself, but where normally get vaccines. Additional Vaccines Administered on Same Date of the Pfizer Suspect If applicable, list all vaccines administered on same date with the Pfizer vaccine considered as suspect: no. Prior Vaccinations (within 4 weeks) If applicable, list any other vaccinations within four weeks prior to the first administration date of the suspect vaccine(s): no. Adverse events following prior vaccination: No. Other products and investigation Assessment was reported as No. Relevant test: None.   No follow-up attempts are possible. No further information is expected.